FDA Seeks Regulatory Science ‘Bridge’ To Find Pharmacogenomics Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
Incoming Acting Commissioner Stephen Ostroff co-authors paper urging standardization of bioinformatics to speed development of safety and efficacy markers.
You may also be interested in...
From “Safe Harbor” To Spotlight: Pharmacogenomics Comes Of Age At FDA
An FDA/industry workshop on pharmacogenomics and biomarkers highlighted how far the regulatory system for PKG has evolved. Where industry was afraid to share data with FDA, the conversation is now about how to get the agency the resources it needs to review the data effectively.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.